VentriPoint Diagnostics shares nudge higher as Hirson promoted to president

Hirson was hired in August this year as vice-president, development and operations.
VentriPoint Diagnostics shares nudge higher as Hirson promoted to president
Hirson was hired in August this year as vice-president of development and operations

Shares in medtech firm VentriPoint Diagnostics Ltd (CVE:VPT) nudged 4% higher as it revealed Desmond Hirson had been promoted to the company's president and provided an update on progress.

Hirson was hired in August this year as vice-president, development and operations, and has done an outstanding job of rebuilding the company's operations team, the company said.

Dr George Adams remains as chief executive.

Meanwhile, Dr Alvira Macanovic has been appointed manager of regulatory affairs and quality assurance at VentriPoint.

She has over 10 years' experience in pharmaceutical and medical device industries and worked with researchers, start-ups, SMEs and multinationals to commercialize technologies in multiple therapeutic areas.

The firm's device can analyse all four chambers of the heart using data from a conventional 2D (two dimensional) eco-cardiogram (in other words an ultrasound test).

This year the group reconfigured its VMS machine to accommodate newer ultrasound devices and provide a better form for clinical use.

The VMS+ machine needed to be recertified under ISO60601 specifications for safe medical devices. Testing program is now complete, and the company is awaiting a certificate.

Ventripoint also noted today it has moved its development and manufacturing centre, as well as its corporate offices, to 2 Sheppard Ave, East, suite 605, Toronto, Ontario.

Shares added 4% to C$0.26 on the day.

View full VPT profile View Profile

VentriPoint Diagnostics Timeline

Related Articles

Frosties Box
December 04 2017
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin
Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
Copyright © personabelovo.ru, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.